

# Paul Thomas Francis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1513747/publications.pdf>

Version: 2024-02-01

235  
papers

13,083  
citations

20817

60  
h-index

27406

106  
g-index

246  
all docs

246  
docs citations

246  
times ranked

14256  
citing authors

#	ARTICLE	IF	CITATIONS
1	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	3.8	8
2	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. <i>Molecular Psychiatry</i> , 2021, 26, 5766-5788.	7.9	63
3	Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias. <i>Brain Pathology</i> , 2021, 31, 253-266.	4.1	21
4	Striatal Dopaminergic Deficit and Sleep in Idiopathic Rapid Eye Movement Behaviour Disorder: An Explorative Study. <i>Nature and Science of Sleep</i> , 2021, Volume 13, 1-9.	2.7	12
5	Cerebral amyloid angiopathy distribution in older people: A cautionary note. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12145.	3.7	10
6	Concomitant neurodegenerative pathologies contribute to the transition from mild cognitive impairment to dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 1121-1133.	0.8	40
7	A meta-analysis of epigenome-wide association studies in Alzheimer's disease highlights novel differentially methylated loci across cortex. <i>Nature Communications</i> , 2021, 12, 3517.	12.8	72
8	Language Barrier in Anganwadis in Eranakulam, Kerala. <i>Indian Pediatrics</i> , 2021, 58, 793-794.	0.4	0
9	Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2021, 398, 1487-1497.	13.7	31
10	Language Barrier in Anganwadis in Eranakulam, Kerala. <i>Indian Pediatrics</i> , 2021, 58, 793-794.	0.4	0
11	A rare loss-of-function variant of ADAM17 is associated with late-onset familial Alzheimer disease. <i>Molecular Psychiatry</i> , 2020, 25, 629-639.	7.9	42
12	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	1.2	38
13	Recalibrating the epigenetic clock: implications for assessing biological age in the human cortex. <i>Brain</i> , 2020, 143, 3763-3775.	7.6	100
14	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease. <i>Brain</i> , 2020, 143, 3842-3849.	7.6	17
15	Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 512-519.	1.9	75
16	Genetic risk for Alzheimer's disease influences neuropathology via multiple biological pathways. <i>Brain Communications</i> , 2020, 2, fcaa167.	3.3	9
17	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. <i>Brain Pathology</i> , 2019, 29, 63-74.	4.1	48
18	Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer's disease are not present in diabetic Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 11386.	3.3	16

#	ARTICLE	IF	CITATIONS
19	Age-related neurochemical and behavioural changes in D409V/WT GBA1 mouse: Relevance to lewy body dementia. <i>Neurochemistry International</i> , 2019, 129, 104502.	3.8	10
20	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019, 9, 154.	4.8	69
21	Brains for Dementia Research: The Importance of Cohorts in Brain Banking. <i>Neuroscience Bulletin</i> , 2019, 35, 289-294.	2.9	6
22	Transgenerational preventive practices of diabetes mellitus type II patients attending a tertiary care hospital in Cochin, India. <i>Indian Journal of Community Medicine</i> , 2019, 44, 7.	0.4	0
23	Impact of Swachh Bharat Abhiyan on residents of Cochin corporation. <i>Indian Journal of Community Medicine</i> , 2019, 44, 19.	0.4	1
24	Assessment of respiratory morbidity among bus drivers and conductors of the state road transport corporation, Kochi, Kerala. <i>Journal of Family Medicine and Primary Care</i> , 2019, 8, 3887.	0.9	3
25	Vaccine Preventable Diseases (VPD) and Public Health. <i>Indian Pediatrics</i> , 2019, 56, 1064.	0.4	0
26	The effect of phloretin on synaptic proteins and adult hippocampal neurogenesis in $\beta$ 2 (1-42)-injected male Wistar rats. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1022-1030.	2.4	12
27	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	7.6	172
28	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analysis. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 232-241.	1.7	49
29	Whole-exome sequencing of the BDR cohort: evidence to support the role of the <i>PILRA</i> gene in Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2018, 44, 506-521.	3.2	35
30	Ticking boxes or meaningful partnership? The experience of lay representation, participant and study partner involvement in Brains for Dementia Research. <i>Dementia</i> , 2018, 17, 1023-1034.	2.0	7
31	Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1635-1644.	2.6	24
32	Factors affecting withdrawal and donation attrition in the brains for dementia research cohort. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1709-1716.	2.7	1
33	Observations of extensive gene expression differences in the cerebellum and potential relevance to Alzheimer's disease. <i>BMC Research Notes</i> , 2018, 11, 646.	1.4	12
34	Associations between ZnT3, tau pathology, agitation, and delusions in dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1146-1152.	2.7	11
35	Genotyping of the Alzheimer's Disease Genome-Wide Association Study Index Single Nucleotide Polymorphisms in the Brains for Dementia Research Cohort. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 355-362.	2.6	6
36	Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 5177-5183.	4.0	21

#	ARTICLE	IF	CITATIONS
37	Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimer's and Dementia</i> , 2017, 13, 84-100.	0.8	167
38	Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer's Disease. <i>Scientific Reports</i> , 2017, 7, 42874.	3.3	36
39	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 373-386.	2.6	14
40	Serotonin 5-HT <sub>6</sub> Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status. <i>CNS Drugs</i> , 2017, 31, 19-32.	5.9	82
41	Increased Transforming Growth Factor $\beta$ 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A $\beta$ 42 Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	2.6	25
42	Correspondence. <i>Indian Pediatrics</i> , 2017, 54, 63-66.	0.4	0
43	A pilot study of potential brain donor satisfaction and attitudes towards telephone assessment. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 1247-1256.	2.7	5
44	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 283-293.	1.5	14
45	Mitochondrial Translocase of the Outer Membrane Alterations May Underlie Dysfunctional Oxidative Phosphorylation in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 793-801.	2.6	19
46	[P1 <sup>235</sup> ]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBUNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P333.	0.8	0
47	Disturbed Matrix Metalloproteinase Pathway in Both Age-Related Macular Degeneration and Alzheimer's Disease. <i>Journal of Neurodegenerative Diseases</i> , 2017, 2017, 1-13.	1.1	15
48	An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias. <i>Molecular Brain</i> , 2017, 10, 36.	2.6	25
49	Utilization of Anganwadi Services in a Rural Population of Kerala. <i>Indian Pediatrics</i> , 2017, 54, 65-66.	0.4	2
50	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 101-110.	2.6	24
51	Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency. <i>Movement Disorders</i> , 2016, 31, 352-359.	3.9	66
52	An isoform-specific role of Fyn tyrosine kinase in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2016, 136, 637-650.	3.9	20
53	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 352-365.	3.2	41
54	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	2.8	3

#	ARTICLE	IF	CITATIONS
55	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, 1149-1158.	0.8	126
56	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with $\beta$ -amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	2.6	26
57	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 349-361.	2.6	9
58	Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients. <i>Psychopharmacology</i> , 2016, 233, 591-598.	3.1	14
59	Differential Alterations of Neocortical GluN Receptor Subunits in Patients with Mixed Subcortical Ischemic Vascular Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 431-437.	2.6	4
60	Dietary ( $\gamma$ )-epicatechin as a potent inhibitor of $\beta$ -secretase amyloid precursor protein processing. <i>Neurobiology of Aging</i> , 2015, 36, 178-187.	3.1	76
61	Spreading Pathologies Precede Cognitive Decline in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 678-679.	1.3	1
62	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. <i>Neuroscience Letters</i> , 2015, 594, 137-143.	2.1	14
63	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 141-148.	1.2	38
64	Stage-Specific Changes in Neurogenic and Glial Markers in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2015, 77, 711-719.	1.3	67
65	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	4.1	144
66	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 2836-2844.	3.1	94
67	Dynamin protein in stroke and vascular dementia. <i>Neuroscience Letters</i> , 2014, 563, 118-122.	2.1	3
68	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	2.8	3
69	Serotonergic Therapies for Cognitive Symptoms in Alzheimer's Disease: Rationale and Current Status. <i>Drugs</i> , 2014, 74, 729-736.	10.9	77
70	Decreased rabphilin 3A immunoreactivity in Alzheimer's disease is associated with $\beta$ amyloid burden. <i>Neurochemistry International</i> , 2014, 64, 29-36.	3.8	41
71	Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia. <i>Journal of Proteomics</i> , 2014, 99, 54-67.	2.4	30
72	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	1.6	15

#	ARTICLE	IF	CITATIONS
73	CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients. <i>Neurobiology of Aging</i> , 2013, 34, 805-808.	3.1	152
74	Association of a polymorphism in mitochondrial transcription factor A (TFAM) with Parkinson's disease dementia but not dementia with Lewy bodies. <i>Neuroscience Letters</i> , 2013, 557, 177-180.	2.1	29
75	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013, 9, 602-608.	0.8	292
76	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	2.7	54
77	Randomized controlled trial of mibampator for behavioral and psychological symptoms of dementia: comments on the trial and thoughts for future studies. <i>International Psychogeriatrics</i> , 2013, 25, 687-689.	1.0	2
78	Clusterin Associates Specifically with $\tau^{240}$ in Alzheimer's Disease Brain Tissue. <i>Brain Pathology</i> , 2013, 23, 623-632.	4.1	28
79	Safety and Efficacy of Memantine Extended-Release in the Management of Alzheimer's Disease. <i>Clinical Medicine Insights Therapeutics</i> , 2013, 5, CMT.S7794.	0.4	0
80	Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates A $\beta$ production. <i>Human Molecular Genetics</i> , 2012, 21, 2845-2854.	2.9	100
81	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2012, 379, 528-536.	13.7	144
82	Pro-oxidant diet enhances $\beta$ 2/ $\beta$ 3 secretase-mediated APP processing in APP/PS1 transgenic mice. <i>Neurobiology of Aging</i> , 2012, 33, 960-968.	3.1	32
83	Tau phosphorylation in human brain: relationship to behavioral disturbance in dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2798-2806.	3.1	35
84	Memantine potentiates hippocampal theta oscillations at a therapeutic dose in anesthetized mice: A mechanistic link to its cognitive-enhancing properties. <i>Neuropharmacology</i> , 2012, 62, 2208-2218.	4.1	24
85	Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1351-1365.	2.8	39
86	Proteasome inhibition leads to early loss of synaptic proteins in neuronal culture. <i>Journal of Neural Transmission</i> , 2012, 119, 1467-1476.	2.8	10
87	Synaptic protein expression is regulated by a pro-oxidant diet in APPxPS1 mice. <i>Journal of Neural Transmission</i> , 2012, 119, 493-496.	2.8	0
88	Identification of Novel $\beta$ -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	3.3	99
89	Cholinergic imbalance in the multiple sclerosis hippocampus. <i>Acta Neuropathologica</i> , 2011, 122, 313-322.	7.7	63
90	Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease. <i>Psychopharmacology</i> , 2011, 213, 431-439.	3.1	39

#	ARTICLE	IF	CITATIONS
91	Antipsychotic medication is associated with selective alterations in ventricular cerebrospinal fluid A $\beta$ <sup>2</sup> 40 and tau in patients with intractable unipolar depression. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1283-1291.	2.7	7
92	Synthesis, physical-chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4(1H)-ones: Iron chelators with the potential for treating Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1285-1297.	3.0	45
93	Genetic Associations of Autopsy-Confirmed Vascular Dementia Subtypes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 247-253.	1.5	19
94	A Double-Blind Placebo-Controlled Randomized Trial of <i>Melissa officinalis</i> Oil and Donepezil for the Treatment of Agitation in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 158-164.	1.5	129
95	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1515-1522.	2.4	36
96	Pharmacological profile of an essential oil derived from <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 377-384.	2.4	44
97	$\beta$ -synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	1.0	20
98	Vesicular glutamate transporter and cognition in stroke. <i>Neurology</i> , 2010, 75, 1803-1809.	1.1	34
99	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. <i>Archives of General Psychiatry</i> , 2010, 67, 739.	12.3	353
100	A serotonergic basis for hyperphagic eating changes in Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2010, 288, 151-155.	0.6	38
101	Neurochemical changes in a double transgenic mouse model of Alzheimer's disease fed a pro-oxidant diet. <i>Neurochemistry International</i> , 2010, 57, 504-511.	3.8	8
102	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. <i>Neurochemistry International</i> , 2010, 57, 985-989.	3.8	59
103	Neurochemical basis for symptomatic treatment of Alzheimer's disease. <i>Neuropharmacology</i> , 2010, 59, 221-229.	4.1	94
104	Altered NCAM Expression Associated with the Cholinergic System in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 659-668.	2.6	38
105	Altered Glutamate Neurotransmission and Behaviour in Dementia: Evidence from Studies of Memantine. <i>Current Molecular Pharmacology</i> , 2009, 2, 77-82.	1.5	47
106	Choline Acetyltransferase Activity in Vascular Dementia and Stroke. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 233-238.	1.5	36
107	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. <i>Brain</i> , 2009, 132, 1858-1865.	7.6	32
108	Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. <i>Journal of Neurology</i> , 2009, 256, 280-285.	3.6	28



#	ARTICLE	IF	CITATIONS
109	AddNeuroMedâ€™The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 2009, 1180, 36-46.	3.8	193
110	Amyloid Î² concentrations in older people with Down syndrome and dementia. <i>Neuroscience Letters</i> , 2009, 451, 162-164.	2.1	31
111	Pharmacological profile of essential oils derived from <i>Lavandula angustifolia</i> and <i>Melissa officinalis</i> with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2009, 61, 267-267.	2.4	0
112	Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. <i>Psychopharmacology</i> , 2008, 196, 603-610.	3.1	62
113	Loss of [3H]4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimerâ€™s disease patients with psychosis. <i>Psychopharmacology</i> , 2008, 198, 251-259.	3.1	17
114	Selective loss of P2Y2 nucleotide receptor immunoreactivity is associated with Alzheimerâ€™s disease neuropathology. <i>Journal of Neural Transmission</i> , 2008, 115, 1165-1172.	2.8	49
115	Neuroprotective actions of deferiprone in cultured cortical neurones and SHSYâ€‘5Y cells. <i>Journal of Neurochemistry</i> , 2008, 105, 2466-2476.	3.9	72
116	Î²1â€‘42 modulation of Akt phosphorylation via Î±7 nAChR and NMDA receptors. <i>Neurobiology of Aging</i> , 2008, 29, 992-1001.	3.1	65
117	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinsonâ€™s Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 330-338.	1.5	48
118	Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 278-286.	1.5	30
119	Glutamatergic Approaches to the Treatment of Cognitive and Behavioural Symptoms of Alzheimerâ€™s Disease. <i>Neurodegenerative Diseases</i> , 2008, 5, 241-243.	1.4	47
120	Involvement of an Altered 5-HT6 Receptor Function in Behavioral Symptoms of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 14, 43-50.	2.6	39
121	Pharmacological profile of essential oils derived from &lt;l&gt;&lt;l&gt;Lavandula angustifolia&lt;/l&gt; and &lt;l&gt;&lt;l&gt;Melissa officinalis&lt;/l&gt; with anti-agitation properties: focus on ligand-gated channels. <i>Journal of Pharmacy and Pharmacology</i> , 2008, 60, 1515-1522.	2.4	39
122	Rationale for Glutamatergic and Cholinergic Approaches for the Treatment of Alzheimerâ€™s Disease. , 2008, , 403-409.		0
123	Genetic variation in the 5-HT2A receptor and altered neocortical [3H] ketanserin binding in Alzheimer's disease. <i>Neuroscience Letters</i> , 2007, 420, 58-60.	2.1	7
124	Surveillance of acute flaccid paralysis in India. <i>Lancet, The</i> , 2007, 369, 1322-1323.	13.7	2
125	Protective efficacy of a monovalent oral type 1 poliovirus vaccine. <i>Lancet, The</i> , 2007, 370, 129.	13.7	1
126	Aggressive Behavior and Neuroleptic Medication Are Associated With Increased Number of Alpha1-Adrenoceptors in Patients With Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 435-437.	1.2	35



#	ARTICLE	IF	CITATIONS
127	Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. <i>Movement Disorders</i> , 2007, 22, S351-S357.	3.9	116
128	Metals ions and neurodegeneration. <i>BioMetals</i> , 2007, 20, 639-654.	4.1	186
129	The Rationale for Glutamatergic Therapy in Alzheimer's Disease. , 2007, , 105-112.		0
130	Involvement of the GABAergic system in depressive symptoms of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1110-1117.	3.1	56
131	Impaired coupling of muscarinic M1 receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1216-1223.	3.1	85
132	Cyclin-dependent kinase 5, Munc18a and Munc18-interacting protein 1/X11± protein up-regulation in Alzheimer's disease. <i>Neuroscience</i> , 2006, 138, 511-522.	2.3	32
133	Targeting Cell Death in Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2006, 20, S3-S7.	1.3	16
134	Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2006, 98, 939-950.	3.9	156
135	Selective effects of the APOE $\epsilon$ 4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2006, 22, 555-561.	4.4	26
136	The Interplay of Neurotransmitters in Alzheimer's Disease. <i>CNS Spectrums</i> , 2005, 10, 6-9.	1.2	217
137	Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. <i>Neuropsychologia</i> , 2005, 43, 442-449.	1.6	193
138	Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. <i>Psychopharmacology</i> , 2005, 179, 673-677.	3.1	83
139	Cholinergic and glutamatergic drugs in Alzheimer's disease therapy. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 671-682.	2.8	16
140	Neurochemistry of severe dementia. <i>Reviews in Clinical Gerontology</i> , 2005, 15, 105-123.	0.5	1
141	A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. <i>Trends in Pharmacological Sciences</i> , 2005, 26, 104-111.	8.7	134
142	Dopaminergic and Glutamatergic Systems in Alzheimer's Disease. , 2005, , 569-581.		0
143	Differential Involvement of 5-HT1B/1D and 5-HT6 Receptors in Cognitive and Non-cognitive Symptoms in Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2004, 29, 410-416.	5.4	128
144	Changes in hippocampal SNAP-25 expression following afferent lesions. <i>Brain Research</i> , 2004, 997, 133-135.	2.2	8

#	ARTICLE	IF	CITATIONS
145	Cholinesterase Inhibitors Used in the Treatment of Alzheimer's Disease. <i>Drugs and Aging</i> , 2004, 21, 453-478.	2.7	287
146	[3H]GR113808 binding to serotonin 5-HT4 receptors in the postmortem neocortex of Alzheimer disease: a clinicopathological study. <i>Journal of Neural Transmission</i> , 2003, 110, 779-788.	2.8	26
147	Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease. <i>Brain Research</i> , 2003, 974, 82-87.	2.2	141
148	Glutamatergic systems in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, S15-S21.	2.7	194
149	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. <i>NeuroReport</i> , 2003, 14, 1297-1300.	1.2	2
150	Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients. <i>NeuroReport</i> , 2003, 14, 1297-1300.	1.2	19
151	Postmortem serotonergic correlates of cognitive decline in Alzheimer's disease. <i>NeuroReport</i> , 2002, 13, 1175-1178.	1.2	84
152	Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. <i>Biological Psychiatry</i> , 2002, 51, 407-416.	1.3	173
153	Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2001, 60, 929-936.	1.7	65
154	Chronic elevation of amyloid precursor protein in the neocortex or hippocampus of marmosets with selective cholinergic lesions. <i>Journal of Neural Transmission</i> , 2001, 108, 809-826.	2.8	11
155	Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 1104-1106.	2.7	6
156	Expression of Amyloid precursor protein, tau and presenilin RNAs in rat hippocampus following deafferentation lesions. <i>Brain Research</i> , 2001, 907, 222-232.	2.2	19
157	Brain aging research at the close of the 20th century: from bench to bedside. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 167-180.	3.7	4
158	Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. <i>Neuropathology and Applied Neurobiology</i> , 2000, 26, 347-355.	3.2	94
159	Cholinergic deficits contribute to behavioral disturbance in patients with dementia. <i>Neurology</i> , 2000, 55, 1460-1467.	1.1	164
160	Neurochemical Features of Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1999, 10, 80-84.	1.5	116
161	The cholinergic hypothesis of Alzheimer's disease: a review of progress. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 137-147.	1.9	1,714
162	Glutamate toxicity in rat cultured neurones: effects on amyloid precursor-like protein 2. <i>Neuroscience Letters</i> , 1999, 276, 107-110.	2.1	4

#	ARTICLE	IF	CITATIONS
163	Postâ€Synaptic 5â€HT<sup>1A</sup> and 5â€HT<sup>2A</sup> Receptors Are Increased in Parkinson's Disease Neocortex. Annals of the New York Academy of Sciences, 1998, 861, 288-289.	3.8	67
164	The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. Journal of Neural Transmission, 1998, 105, 839-853.	2.8	63
165	Current Neurotransmitter Strategies in AD Drug Development. Advances in Behavioral Biology, 1998, , 851-859.	0.2	1
166	The Rationale for Development of Cholinergic Therapies in ad. Advances in Behavioral Biology, 1998, , 445-450.	0.2	0
167	Neuronal Degeneration by Suicide Transport Following Injection of Volkensin into Rat Cerebral Cortex. Experimental Neurology, 1997, 147, 192-203.	4.1	4
168	Selective Loss of Cholinergic Receptors Following Unilateral Intracortical Injection of Volkensin. Experimental Neurology, 1997, 147, 183-191.	4.1	6
169	New Approaches to Imaging Based on Effects of Neurotoxins. Dementia and Geriatric Cognitive Disorders, 1997, 8, 117-122.	1.5	2
170	Glutamatergic Function in Alzheimerâ€™s Disease. , 1997, , 153-159.		0
171	Pyramidal Neurone Modulation: A Therapeutic Target for Alzheimer's Disease. Experimental Neurology, 1996, 5, 461-465.	1.7	16
172	The 5-HT 1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology, 1996, 127, 245-254.	3.1	4
173	Presynaptic Serotonergic Markers in Communityâ€™Acquired Cases of Alzheimer's Disease: Correlations with Depression and Neuroleptic Medication. Journal of Neurochemistry, 1996, 66, 1592-1598.	3.9	116
174	A novel protein, amyloid precursor-like protein 2, is present in human brain, cerebrospinal fluid and conditioned media. Biochemical Journal, 1995, 310, 95-99.	3.7	34
175	SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 600S-600S.	3.4	1
176	NON-SEROTONERGIC PROFILES OF LOBAR ATROPHIES. Biochemical Society Transactions, 1995, 23, 601S-601S.	3.4	1
177	Changes in Cortical Nicotinic Acetylcholine Receptor Numbers Following Unilateral Destruction of Pyramidal Neurones by Intrastratial Volkensin Injection. Experimental Neurology, 1995, 4, 415-424.	1.7	8
178	NMDAâ€™induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5â€HT<sub>1A</sub> antagonist. British Journal of Pharmacology, 1995, 115, 1169-1174.	5.4	65
179	Cholinomimetics Increase Glutamate Outflow via an Action on the Corticostriatal Pathway: Implications for Alzheimer's Disease. Journal of Neurochemistry, 1995, 65, 2165-2169.	3.9	42
180	Brain Membrane Serine Protease Activity in Human Cortex Compared with Rat: Implication for Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 1994, 5, 62-68.	1.5	4

#	ARTICLE	IF	CITATIONS
181	Postmortem brains reveal similar but not identical amyloid precursor protein-like immunoreactivity in Alzheimer compared with other dementias. <i>Brain Research</i> , 1994, 644, 347-351.	2.2	14
182	Neurotransmission—the link integrating Alzheimer research?. <i>Trends in Neurosciences</i> , 1994, 17, 149-150.	8.6	34
183	Glutamatergic Hypoactivity in Alzheimer's Disease: Investigative and Therapeutic Perspectives. , 1994, , 354-358.		0
184	Neuronal pathology in relation to molecular biology and treatment of Alzheimer's disease. , 1994, 4, 25-54.		0
185	Cortical Pyramidal Neurone Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives. <i>Journal of Neurochemistry</i> , 1993, 60, 1589-1604.	3.9	227
186	Localisation of muscarinic (m1) and other neurotransmitter receptors on corticofugal-projecting pyramidal neurones. <i>Brain Research</i> , 1993, 632, 86-94.	2.2	35
187	Soluble $\beta$ -amyloid precursor protein and pyramidal neuron loss. <i>Lancet</i> , The, 1993, 341, 431.	13.7	7
188	Neurotransmitters and Second Messengers in Aging and Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 19-26.	3.8	27
189	Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 80-84.	1.9	22
190	Relationship between $\beta$ -amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. <i>Biochemical Society Transactions</i> , 1993, 21, 238S-238S.	3.4	2
191	Factors affecting the $\beta$ -amyloid precursor in PC12 cells. <i>Biochemical Society Transactions</i> , 1993, 21, 239S-239S.	3.4	5
192	Protease $\alpha$ -Clipsin activity and $\beta$ -amyloid precursor protein degradation by Alzheimer brain. <i>Biochemical Society Transactions</i> , 1993, 21, 241S-241S.	3.4	0
193	Effect of Li <sup>+</sup> therapy and site of origin on cerebrospinal fluid $\beta$ -amyloid precursor protein derivatives. <i>Biochemical Society Transactions</i> , 1993, 21, 242S-242S.	3.4	4
194	A cortical pyramidal neurone neurotransmitter receptor that may affect $\beta$ -amyloid precursor protein. <i>Biochemical Society Transactions</i> , 1993, 21, 240S-240S.	3.4	1
195	Preliminary Neurochemical Findings in Non-Alzheimer Dementia due to Lobar Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 1993, 4, 172-177.	1.5	25
196	Protection from dementia. <i>Science</i> , 1992, 258, 1422-1423.	12.6	7
197	Treatment of Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 328-328.	1.9	5
198	Traditional pharmacotherapy may succeed in Alzheimer's disease. <i>Trends in Neurosciences</i> , 1992, 15, 84-85.	8.6	23

#	ARTICLE	IF	CITATIONS
199	Animal and drug modelling for Alzheimer synaptic pathology. <i>Progress in Neurobiology</i> , 1992, 39, 517-545.	5.7	40
200	Treatment strategies for Alzheimer's disease. <i>Lancet, The</i> , 1992, 339, 132-133.	13.7	46
201	Protease $\alpha$ -Clipsin <sup>TM</sup> extract activity reflects demographic characteristics of human brain. <i>Neuroscience Letters</i> , 1992, 143, 43-47.	2.1	0
202	NMDA receptors assessed by autoradiography with [3H]L-689,560 are present but not enriched on corticofugal-projecting pyramidal neurones. <i>Brain Research</i> , 1992, 596, 223-230.	2.2	20
203	Effect of Psychotropic Drugs on Excitatory Amino Acids in Patients Undergoing Psychosurgery for Depression. <i>British Journal of Psychiatry</i> , 1992, 160, 638-642.	2.8	16
204	Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms. <i>Neurochemical Research</i> , 1992, 17, 917-922.	3.3	67
205	Treatment strategy for the corticocortical neuron pathology of Alzheimer's disease. <i>Annals of Neurology</i> , 1992, 32, 112-112.	5.3	5
206	d-Cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-d-aspartate receptor-ionophore complex in Alzheimer brain. <i>Brain Research</i> , 1991, 565, 345-348.	2.2	63
207	Effect of Central Cholinergic Stimulation on Regional Cerebral Blood Flow in Alzheimer's Disease. <i>British Journal of Psychiatry</i> , 1991, 158, 558-562.	2.8	13
208	Destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from <i>Adenia volkensii</i> . <i>Journal of Neuroscience Methods</i> , 1991, 40, 17-29.	2.5	30
209	Characterisation of the Glycine Modulatory Site of the N-Methyl-d-Aspartate Receptor-Ionophore Complex in Human Brain. <i>Journal of Neurochemistry</i> , 1991, 56, 299-310.	3.9	38
210	Lack of Change in Neurochemical Markers During the Postepileptic Phase of Intrahippocampal Tetanus Toxin Syndrome in Rats. <i>Epilepsia</i> , 1990, 31, 697-701.	5.1	6
211	Spermidine enhancement of [3H]MK-801 binding to the NMDA receptor complex in human cortical membranes. <i>European Journal of Pharmacology</i> , 1990, 189, 195-200.	2.6	21
212	Age-related alteration in excitatory amino acid neurotransmission in rat brain. <i>Neurobiology of Aging</i> , 1990, 11, 155-158.	3.1	50
213	Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. <i>Neuroscience</i> , 1990, 38, 571-577.	2.3	100
214	Tacrine, a Drug with Therapeutic Potential for Dementia: Post-Mortem Biochemical Evidence. <i>Canadian Journal of Neurological Sciences</i> , 1989, 16, 504-510.	0.5	13
215	Pyramidal neuron loss and $\alpha$ -glycine-site therapy: A need for an animal model and study in late-life depression. <i>Neurobiology of Aging</i> , 1989, 10, 616-618.	3.1	8
216	Brain amino acid concentrations and Ca <sup>2+</sup> -dependent release in intractable depression assessed antemortem. <i>Brain Research</i> , 1989, 494, 315-324.	2.2	94

#	ARTICLE	IF	CITATIONS
217	The modulation by chlormethiazole of the GABA <sub>A</sub> receptor complex in rat brain. British Journal of Pharmacology, 1989, 98, 284-290.	5.4	73
218	Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 9504-9508.	7.1	137
219	Evidence of Glutamatergic Denervation and Possible Abnormal Metabolism in Alzheimer's Disease. Journal of Neurochemistry, 1988, 50, 790-802.	3.9	200
220	Topographical distribution of neurochemical changes in Alzheimer's disease. Journal of the Neurological Sciences, 1988, 84, 125-140.	0.6	137
221	Are post-mortem biochemical studies of human brain worthwhile?. Biochemical Society Transactions, 1988, 16, 472-475.	3.4	34
222	The dementia of Alzheimer's disease: an update.. Journal of Neurology, Neurosurgery and Psychiatry, 1987, 50, 242-243.	1.9	20
223	Somatostatin content and release measured in cerebral biopsies from demented patients. Journal of the Neurological Sciences, 1987, 78, 1-16.	0.6	70
224	Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Research, 1987, 414, 365-375.	2.2	138
225	Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Research, 1987, 401, 231-238.	2.2	187
226	Presynaptic Serotonergic Dysfunction in Patients with Alzheimer's Disease. Journal of Neurochemistry, 1987, 48, 8-15.	3.9	211
227	The stability of 5-hydroxyindoleacetic acid and noradrenaline in normal and Alzheimer post mortem brain. Biochemical Society Transactions, 1986, 14, 608-609.	3.4	6
228	Excitatory amino acid neurotransmitters, somatostatin and degenerate cortical neurons in Alzheimer's disease. Biochemical Society Transactions, 1986, 14, 911-912.	3.4	1
229	Relevance of reduced concentrations of somatostatin in Alzheimer's disease. Biochemical Society Transactions, 1985, 13, 170-171.	3.4	14
230	Neurochemical Studies of Early-Onset Alzheimer's Disease. New England Journal of Medicine, 1985, 313, 7-11.	27.0	354
231	The effect of testosterone on the release of endogenous catecholamines from the hypothalamus of the cockerel in vitro. Psychoneuroendocrinology, 1984, 9, 69-76.	2.7	10
232	Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiology of Aging, 1984, 5, 183-186.	3.1	44
233	Changes in Hypothalamic Monoamine Concentrations Accompany the Progesterone-Induced Release of Luteinizing Hormone in the Domestic Hen. Neuroendocrinology, 1982, 35, 359-362.	2.5	10
234	Neurotransmitter Changes in Alzheimer's Disease: Relationships to Symptoms and Neuropathology. , 0, 229-232.		0

#	ARTICLE	IF	CITATIONS
235	Cholinergic and Serotonergic Systems in Severe Dementia. , 0, , 21-31.		0